Cytokinetics EVP Fady Ibraham Malik reports sale of 3,500 shares for $224,035

Cytokinetics EVP of Research and Development Fady Ibraham Malik sold 3,500 common shares at $64.01 each on Oct. 20, 2026, after exercising options to acquire 3,500 shares at $7.80 each. He held 153,902 shares directly after the transactions.